Apollo Medical Holdings, Inc. AMEH Cash Flow

Apollo medical holdings, inc. (AMEH)

CashFlow / TTM

Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Jan'14	Dec'13	Oct'13	Sep'13	Jul'13	Jun'13	Apr'13	Mar'13	Jan'13	Oct'12	Jul'12	Apr'12	Jan'12	Oct'11	Jul'11	Apr'11
Cash flows from operating activities
Net income
17,673	17,011	44,898	42,099	60,267	104,375	61,516	49,818	45,824	2,173	4,935	7,869	-7,970	-8,019	-6,842	-8,173	-4,042	-3,900	-2,070	-1,347	-2,073	-1,647	-4,163	-4,589	-	-4,023	-	-3,881	-	-7,622	0	-8,892	-8,904	-8,508	-3,728	-648	-720	0	0	0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
18,753	18,276	18,198	18,662	19,303	28,747	24,060	19,297	19,075	5,296	5,311	5,320	548	545	452	351	222	270	386	334	405	217	30	24	-	23	-	23	-	22	0	20	20	17	16	14	12	0	0	0
Loss on disposal of property and equipment
0	-0	-0	-0	-41	-41	-41	-41	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for doubtful accounts
-	-	-	0	-	-	-	22	0	406	224	385	400	505	603	435	0	0	0	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share-based compensation
1,546	1,208	1,080	952	1,441	3,241	3,234	3,255	2,743	1,090	1,141	1,165	1,768	1,445	1,267	1,103	305	435	1,223	1,258	1,192	1,013	725	2,158	-	2,144	-	0	-	0	-	0	-	-	-	-	-	-	-	-
Unrealized (gain) loss from investment in equity securities
9	-8	5	-8	-25	-3	69	77	86	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on debt extinguishment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Issuance of shares for services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	-	1,311	191	132	152	0	0	0
Non-cash stock option expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	-	517	97	83	29	0	0	0
Amortization of deferred financing costs
-	-	-	-	-	-	-	-	-	114	60	44	55	86	102	94	107	106	123	121	117	253	211	195	-	178	-	41	-	69	0	77	89	71	59	49	37	0	0	0
Amortization adjustment to debt discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-29	69	174	436	400	307	158	131	96	-	92	-	460	-	551	0	0	670	490	327	164	0	0	0	0
Change in fair value of derivative instrument
-	-	-	-	-	-	-	-	-44	1,822	2,333	3,155	911	1,041	627	-408	666	594	649	833	480	122	-30	0	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Income (Loss) from Equity Method Investments
-6,900	-4,390	-10,659	-8,946	-8,125	-3,656	-902	-3,367	-1,112	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax
-6,800	-15,666	-9,601	-13,775	-8,345	-7,809	-15,549	-19,977	-20,675	0	0	0	-	-	-	-127	-55	-105	-48	-51	17	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on sale of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on change in fair value of warrant and derivative liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	5,853	0	0	0	-	-	-	-
Changes in operating assets and liabilities, net of acquisition amounts:
Restricted cash
-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivable, net
-10,713	2,842	4,085	1,072	263	6,376	5,967	9,004	-4,108	-13,470	-12,506	-11,656	2,731	1,067	910	27	110	132	807	912	849	901	-73	-415	-	-255	-	220	-	50	0	0	548	-339	-406	-242	-407	0	0	0
Receivable, net – related parties
1,435	-20,861	33,793	13,242	28,363	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other receivable
15,079	13,719	11,897	11,244	0	-62	-496	-154	0	85	494	-113	-455	-654	-669	-283	79	-5,113	308	188	12	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Due to officers
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	-12	0	0	0	-	-	-	-
Due from affiliates
-	-	-	-	-	-	-	-	-	-20	-20	-2	-1	0	-31	-15	8	-29	-61	-55	-57	-20	42	4	-	-5	-	-26	-	-25	0	0	-5	0	0	0	-	-	-	0
Prepaid expenses and other current assets
2,755	5,646	2,781	3,774	2,813	-1,637	1,070	-1,921	-1,260	527	432	634	226	97	328	92	191	234	92	118	-14	9	-14	-19	-	-20	-	-39	-	-3	0	2	23	-0	6	-1	-22	0	0	0
Right-of-use assets
2,479	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid commission and financing cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	43	-517	-513	-513	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other assets
572	495	145	380	-2	199	265	226	220	48	59	59	1	8	0	-3	4	99	102	106	105	-6	-6	-3	-	-6	-	-4	-	-8	0	0	-7	0	0	0	-	-	-	0
Accounts payable and accrued expenses
-4,883	-49,502	-18,637	1,079	-22,669	31,206	-10,357	-2,505	-3,687	82	9,543	896	3,900	-594	-83	1,024	616	272	1,646	851	1,228	2,883	591	706	-	135	-	798	-	858	0	0	764	490	-154	79	70	0	0	0
Incentives payable
-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fiduciary accounts payable
488	195	983	1,177	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent liability
-	-	-	-	-	-	-	-	-	-100	-12	53	134	148	91	57	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Medical liabilities
-2,391	28,374	-2,565	-11,380	4,134	-53,473	-9,149	11,057	5,661	28,379	16,961	-1,147	-157	732	1,364	1,410	96	-342	-26	249	831	553	53	-114	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Income taxes payable
-7,092	106	-2,900	5,217	8,423	-14,257	-3,772	536	388	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in cash on consolidation of variable interest entity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by operating activities
13,673	3,715	-9,937	16,793	25,496	41,045	40,547	35,463	51,833	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	0	57	177	-396	-401	-385	0	0	0
Net cash provided by (used in) operating activities
-	-	-	-	-	-	-	-	-	-	16,743	-	-	-	-3,577	-	-2,752	1,521	298	-271	643	-2,672	-2,122	-863	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Cash flows from investing activities
Purchases of marketable securities
115,402	21	13	13	9	9	7	7	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Advances on loans receivable
-	-	-	-	-	-	-	-	10,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Equity Method Investment, Distribution, Return of Capital
-	-	-	-	-	-	-	-	1,240	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liabilities
-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to Acquire Businesses, Net of Cash Acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,356	3,076	1,928	13	229	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Proceeds on sale of investments - cost method
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment
1,041	1,108	863	788	1,170	2,577	2,412	2,251	2,084	429	450	578	355	425	425	262	173	71	32	44	49	36	27	22	-	13	-	37	-	44	0	0	45	0	0	0	-	-	-	-
Net cash (used in) provided by investing activities
-180,630	-65,298	-55,163	-24,805	-25,182	10,819	11,170	30,522	26,716	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	0	-31	0	0	0	-	-	-	-
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-1,263	-	-	-	-410	-	-691	-1,279	-3,404	-3,200	-2,686	-1,964	-40	-252	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Cash flows from financing activities
Repayment of bank loan and lines of credit
-	0	0	394	-	0	0	140	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Dividends paid
61,717	61,703	16,700	25,758	17,758	17,683	12,957	3,697	10,447	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from notes and line of credit payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Principal payments on lines of credit
-	-	-	-	-	-	-	-	-	125	175	150	106	1,068	1,018	1,006	0	0	0	-	-	-	-	2,811	0	-	0	-	-	0	-	0	-	-	-	-	-	-	-	-
Change in noncontrolling interest capital
-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Borrowings on line of credit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	0	0	-	-	-	-
Principal payments on notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	936	813	1,241	634	459	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Payment of capital lease obligations
101	100	100	99	98	97	96	95	102	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of medical clinic acquisition notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Repayments on convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options and warrants
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options and warrants
3,123	2,822	2,547	2,212	3,996	3,659	2,432	0	-	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Increase in restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of convertible note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-728	-	-430	0	0	0	0	0	0	-	-	-	-
Proceeds from issuance of convertible notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	0	880	0	0	0	-	-	-	-
Cash payments in connection with convertible note redemption
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Debt issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	535	-	303	-	0	0	-	0	0	104	0	0	0	-	-	-	-
Proceeds from common stock offering
754	754	205	355	200	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Distributions to non-controlling interest shareholder
-	-	-	-	-	-	-	-	-	150	750	1,200	1,307	1,157	557	702	595	595	1,195	600	800	800	320	440	-	240	-	540	-	420	0	0	400	0	0	0	-	-	-	-
Repurchase of common shares
7,569	5,087	5,087	5,087	5,047	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
-	-	-	-	-	-	-	-	-	-	9,217	-	-	-	6,606	-	1,137	-266	1,234	1,655	7,543	7,568	6,518	6,908	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Net cash used in financing activities
163,330	167,904	12,185	-20,745	-11,176	-12,013	-7,586	-6,833	-14,975	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	0	986	0	0	0	-	-	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash
-	-	-	-28,757	-	-	-	59,152	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of cash flow information
Interest paid
-	-	-	-	-	-	-	-	-	-	16	-	-	-	427	-	753	793	719	768	598	789	648	603	-	536	-	315	-	251	0	0	160	80	81	143	129	0	0	0
Cash paid for income taxes
20,200	23,510	28,730	23,642	23,642	40,866	34,446	22,851	24,362	1,526	1,525	1,524	96	160	160	176	107	45	53	32	22	27	52	47	-	53	-	39	-	7	0	0	9	0	0	0	-	-	0	0
Cash paid for interest
4,257	1,174	756	570	462	336	194	123	51	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosures of non-cash investing and financing activities
Cashless exercise of stock options
0	0	0	0	0	0	0	-0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
APC stock issued in exchange for AMG
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	280	0	0	0
Deferred tax liability adjusted to goodwill
6,334	11,539	8,355	196	1,110	1,110	1,110	914	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cumulative effect adjustment for ASC 606 included in accounts receivable
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cumulative effect adjustment for ASC 606 included in deferred tax liabilities
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Holdback liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	-	0	-	0	-	-	-	-	-	-	-	-	-	-
Convertible note warrant
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible note conversion feature
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition related warrant consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition related consideration fair value of units issued by consolidated subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Acquisition related deferred tax liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pre-acquisition net equity of noncontrolling interest in variable interest entity
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of fiduciary cash to payable
-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reconciliation of cash, cash equivalents, and restricted cash
Net change in cash and cash equivalents
-	-	-	-	-	-	-	-	-	26,410	24,696	-605	-656	-131	2,619	4,255	-2,307	-25	-1,871	-1,817	5,500	2,931	4,355	5,793	-	331	-	897	-	1,351	0	0	1,012	251	-84	-87	-232	0	0	0
NNA term loan discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Shares issued in connection with convertible notes redemption
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Fair value of warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
NNA shares issuance discount
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Warrants issued in connection with convertible note issuance
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	0	387	0	0	0	-	-	-	-
Contingent consideration payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Shares issuable and issued for deferred financing costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	45	-	0	-	0	-	0	0	198	0	0	0	-	-	-	-
Notes payable issued in connection with medical clinic acquisitions
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement of stock issuable liability with issuance of shares
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair value of embedded conversion feature reacquired in connection with convertible notes redemption
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued for prepaid director services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	0	0	-	-	-	-